H.C. Wainwright Reiterates Buy on Revolution Medicines
The large target-implied upside is notable, but this is a reiterated rating from one analyst and should be treated as an opinion rather than a forecast.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The large target-implied upside is notable, but this is a reiterated rating from one analyst and should be treated as an opinion rather than a forecast.
What happened, with direct paths to the underlying reporting
H.C. Wainwright reiterated its Buy rating on RVMD with a $350 target, about 110% above the posted price of $166.87.
Target: $350
Posted price: $166.87
Analyst firm: H.C. Wainwright
Analyst: Raghuram Selvaraju
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.